Evidence map›Paper›PMID 22792062›Full record

ArticlePLoS pathogens2012

Proteomic profiling of the TRAF3 interactome network reveals a new role for the ER-to-Golgi transport compartments in innate immunity.

Wendy J van Zuylen, Priscilla Doyon, Jean-François Clément, Kashif Aziz Khan, Lisa M D'Ambrosio, Florence Dô, Myriam St-Amant-Verret, Tasheen Wissanji, Gregory Emery, Anne-Claude Gingras and 2 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Article
  3. The Golgi Apparatus: A Key Player in Innate Immunity.International journal of molecular sciences · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. TRAF3 can interact with GMEB1 and modulate its anti-apoptotic function.Journal of biological research (Thessalonike, Greece) · 2020
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Mint3 potentiates TLR3/4- and RIG-I-induced IFN-β expression and antiviral immune responses.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Wendy J van ZuylenFaculty of Pharmacy, Université de Montréal, Montréal, Québec Canada.
Priscilla Doyon
Jean-François Clément
Kashif Aziz Khan
Lisa M D'Ambrosio
Florence Dô
Myriam St-Amant-Verret
Tasheen Wissanji
Gregory Emery
Anne-Claude Gingras
Sylvain Meloche
Marc J Servant
Université de Montréal · CAInstitute for Research in Immunology and Cancer · CAMount Sinai Hospital · CAUniversity of Toronto · CA

Funding

Canadian Institutes of Health Research MOP-84314Canadian Institutes of Health Research MOP-84571
6 · The paper itself

Abstract

Tumor Necrosis Factor receptor-associated factor-3 (TRAF3) is a central mediator important for inducing type I interferon (IFN) production in response to intracellular double-stranded RNA (dsRNA). Here, we report the identification of Sec16A and p115, two proteins of the ER-to-Golgi vesicular transport system, as novel components of the TRAF3 interactome network. Notably, in non-infected cells, TRAF3 was found associated with markers of the ER-Exit-Sites (ERES), ER-to-Golgi intermediate compartment (ERGIC) and the cis-Golgi apparatus. Upon dsRNA and dsDNA sensing however, the Golgi apparatus fragmented into cytoplasmic punctated structures containing TRAF3 allowing its colocalization and interaction with Mitochondrial AntiViral Signaling (MAVS), the essential mitochondria-bound RIG-I-like Helicase (RLH) adaptor. In contrast, retention of TRAF3 at the ER-to-Golgi vesicular transport system blunted the ability of TRAF3 to interact with MAVS upon viral infection and consequently decreased type I IFN response. Moreover, depletion of Sec16A and p115 led to a drastic disorganization of the Golgi paralleled by the relocalization of TRAF3, which under these conditions was unable to associate with MAVS. Consequently, upon dsRNA and dsDNA sensing, ablation of Sec16A and p115 was found to inhibit IRF3 activation and anti-viral gene expression. Reciprocally, mild overexpression of Sec16A or p115 in Hec1B cells increased the activation of IFNβ, ISG56 and NF-κB -dependent promoters following viral infection and ectopic expression of MAVS and Tank-binding kinase-1 (TBK1). In line with these results, TRAF3 was found enriched in immunocomplexes composed of p115, Sec16A and TBK1 upon infection. Hence, we propose a model where dsDNA and dsRNA sensing induces the formation of membrane-bound compartments originating from the Golgi, which mediate the dynamic association of TRAF3 with MAVS leading to an optimal induction of innate immune responses.

Indexed as

Immunity, InnateAdaptor Proteins, Signal TransducingCell LineDNAEndoplasmic ReticulumGene Expression ProfilingGolgi ApparatusGolgi Matrix ProteinsHEK293 CellsHeLa CellsHumansInterferon-betaInterferon Regulatory Factor-3MitochondriaNF-kappa BPromoter Regions, GeneticAdaptor Proteins, Signal TransducingDNAGolgi Matrix ProteinsIFIT1 protein, humanInterferon-betaInterferon Regulatory Factor-3IRF3 protein, humanMAVS protein, humanNF-kappa BProtein Serine-Threonine KinasesProteomeRNA-Binding ProteinsRNA, Double-StrandedRNA, Small InterferingSEC16A protein, humanTBK1 protein, humanTNF Receptor-Associated Factor 3TRAF3 protein, humanTranscription Factorsvesicular transport factor p115Vesicular Transport Proteins

Identifiers

PMID22792062
PMCPMC3390413
OpenAlexW2003861253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.